You are here

  • Home
  • Archive
  • Volume 75, Issue Suppl 2
  • THU0040 Impact of Baseline Conventional Disease Activity Variables, Imaging Assessment of RA Activity (Joint US and MRI Synovitis Scores), MMP-3 and Calprotectin Levels on Achievement of ACR70 Response in RA Patients after Etanercept Treatment

Article Text

Article menu
Download PDFPDF
Poster Presentations
Rheumatoid arthritis - prognosis, predictors and outcome
THU0040 Impact of Baseline Conventional Disease Activity Variables, Imaging Assessment of RA Activity (Joint US and MRI Synovitis Scores), MMP-3 and Calprotectin Levels on Achievement of ACR70 Response in RA Patients after Etanercept Treatment
  1. A. Pchelintseva1,
  2. E. Panasyuk1,
  3. N. Ionichenok1,
  4. A. Zhornyak1,
  5. A. Ilyina1,
  6. I. Andrianova1,
  7. M. Cherkasova2,
  8. M. Severinova3,
  9. A. Volkov3,
  10. A. Smirnov4,
  11. L. Denisov1
  1. 1Department of Clinical Trials
  2. 2Laboratory of Immunology and Molecular Biology of the Rheumatic Diseases
  3. 3Diagnostic Department
  4. 4Department of Radiology, Nasonova Research Institute of Rheumatology, Moscow, Russia, Moscow, Russian Federation

Abstract

Background Monitoring of RA activity is important in daily practice and clinical trials, in particular for subjects receiving biologics. As a result, new imaging tools and more objective biomarkers of synovial inflammation and joint destruction have been developed.

Objectives To evaluate role of imaging methods (joint MRI, US), biomarkers (calprotectin-CP and MMP-3) and RA activity parameters in achievement of ACR70 response after Etanercept (ETN) therapy

Methods 25 pts (mean age 49,4±13,7 yrs) with active RA despite stable doses of cDMARDs (DAS28 6,12±0,97) had received ETN 50 mg weekly sc for 24 weeks. RA duration was 6,38±5,9 yrs, 92% were women, 64%>RF+. Clinical and laboratory evaluation was done at weeks 0 and 25. US exam was performed before start of ETN treatment and after 6 month of ETN therapy by the same independent sonographer. 7-joint score (grade 0–3) included wrist, intercarpal, 2–3 MCP, 2–3 PIP joints of the clinically dominant hand and knee was used. MRI was done at baseline and after end of ETN treatment. Assessment of 2–5 MCP joints of the clinically dominant hand (0-no synovitis, 1–10-severity of synovitis) was done by the same independent radiologist.CP and MMP-3 serum levels (ELISA) were measured at the same time points. Changes of all parameters since baseline were assessed. Predictive factors of achievement ACR70 responce were explored.

Results All clinical, laboratory, MRI and US parameters of RA activity had significantly improved during ETN therapy (p<0,05).We detected statistically significant difference only in baseline MRI synovitis score between responders and non-responders according ACR70 (p=0,0074). (table 1)

View this table:
Table 1.

The difference in baseline variables between ACR70 responders and non-responders

We did not find any significant difference between groups in MeΔ at weeks 0–12 of ESR, CRP, CP and MMP-3, whereas MeΔ of SJC distinguished in ACR70 responders and non-responders (p=0,0494).

Conclusions 1. US and MRI synovitis sum scores decreased significantly in parallel with CP and MMP-3 serum levels and RA activity variables during ETN therapy. 2. Low baseline MRI synovitis sum score is more useful in comparison with baseline US, CP, MMP-3 and conventional RA activity factors as predictive tool of good responce in RA during anti-TNF therapy. 3. Decrease of ESR, CRP, CP and MMP-3 at week 12 had not impact on ACR70 response at week 25.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2016-eular.2235

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.